Markus Kajo Schuler1, Ivan Platzek2, Bettina Beuthien-Baumann3, Michael Fenchel4, Gerhard Ehninger5, Jörg van den Hoff6. 1. Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstraße 74, 01307, Dresden. Electronic address: markus.schuler@uniklinikum-dresden.de. 2. Department of Radiology, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstraße 74, 01307, Dresden. 3. Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstraße 74, 01307, Dresden. 4. General Practice of Radiology, Berlin. 5. Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Fetscherstraße 74, 01307, Dresden. 6. PET Center Rossendorf, Bautzner Landstraße 400, 01328, Dresden.
Abstract
BACKGROUND: (18)F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) has proven to be of substantial benefit in imaging of sarcoma patients. We therefore investigated the feasibility and benefit of combined PET/magnetic resonance imaging (MRI). METHODS: Twelve patients with sarcoma who underwent FDG PET/MRI for staging and response assessment after chemotherapy were included. RESULTS: Based on contrast-enhanced MRI and application of Choi criteria, therapy response was classified as stable disease in 6/12 patients (50%) and as partial remission in 6/12 patients (50%). CONCLUSION: In sarcoma patients, response assessment using Choi criteria based on contrast-enhanced MRI in comparison to FDG PET imaging only demonstrates slight correlation.
BACKGROUND: (18)F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) has proven to be of substantial benefit in imaging of sarcomapatients. We therefore investigated the feasibility and benefit of combined PET/magnetic resonance imaging (MRI). METHODS: Twelve patients with sarcoma who underwent FDG PET/MRI for staging and response assessment after chemotherapy were included. RESULTS: Based on contrast-enhanced MRI and application of Choi criteria, therapy response was classified as stable disease in 6/12 patients (50%) and as partial remission in 6/12 patients (50%). CONCLUSION: In sarcomapatients, response assessment using Choi criteria based on contrast-enhanced MRI in comparison to FDG PET imaging only demonstrates slight correlation.
Authors: Youssef Erfanian; Johannes Grueneisen; Julian Kirchner; Axel Wetter; Lars Erik Podleska; Sebastian Bauer; Thorsten Poeppel; Michael Forsting; Ken Herrmann; Lale Umutlu Journal: Eur J Nucl Med Mol Imaging Date: 2017-05-31 Impact factor: 9.236